Edition:
United States

Peregrine Pharmaceuticals Inc (PPHM.OQ)

PPHM.OQ on NASDAQ Stock Exchange Capital Market

3.86USD
15 Dec 2017
Change (% chg)

$-0.21 (-5.16%)
Prev Close
$4.07
Open
$4.00
Day's High
$4.00
Day's Low
$3.82
Volume
89,380
Avg. Vol
57,101
52-wk High
$5.77
52-wk Low
$1.98

Chart for

About

Peregrine Pharmaceuticals, Inc. (Peregrine) is a biopharmaceutical company. The Company operates through two segments: Peregrine, which is engaged in the research and development of monoclonal antibodies for the treatment of cancer, and Avid, which is engaged in providing contract manufacturing services for third party customers... (more)

Overall

Beta: 2.79
Market Cap(Mil.): $174.52
Shares Outstanding(Mil.): 45.21
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.20 16.04
EPS (TTM): -- -- --
ROI: -- 15.06 34.69
ROE: -- 16.55 15.46

BRIEF-Peregrine Pharma reports Q2 shr loss $0.31

* PEREGRINE PHARMACEUTICALS REPORTS FINANCIAL RESULTS FOR SECOND QUARTER OF FISCAL YEAR 2018 AND RECENT DEVELOPMENTS

Dec 11 2017

BRIEF-Peregrine Pharma, Ronin Trading And SW Investment Management Announce Settlement Agreement

* PEREGRINE PHARMACEUTICALS, RONIN TRADING AND SW INVESTMENT MANAGEMENT ANNOUNCE SETTLEMENT AGREEMENT

Nov 28 2017

BRIEF-Ronin Trading and SW Investment Management announce additional nominations to board of Peregrine pharmaceuticals

* Ronin Trading and SW Investment Management announce additional nominations to board of peregrine pharmaceuticals

Oct 27 2017

BRIEF-Peregrine Pharmaceuticals appoints Mark Bamforth to board of Avid Bioservices and co

* Peregrine Pharmaceuticals announces appointment of Mark R. Bamforth to board of directors of Peregrine and Avid Bioservices Source text for Eikon: Further company coverage:

Oct 19 2017

BRIEF-Ronin Trading, SW Investment Management nominate James Egan to Peregrine Pharmaceuticals Board

Oct 10 Ronin Trading, LLC and SW Investment Management LLC:

Oct 10 2017

BRIEF-Peregrine Pharmaceuticals reports Q1 loss per share $0.06

* Peregrine Pharmaceuticals reports financial results for first quarter of fiscal year 2018 and recent developments

Sep 11 2017

BRIEF-Peregrine Pharma appoints Roger Lias as Avid Bioservices president

* Peregrine Pharmaceuticals announces appointment of Roger J. Lias, PH.D. as president of Avid Bioservices

Sep 11 2017

BRIEF-Peregrine announces measures to reduce costs, facilitate profitability and strengthen its operations

* Peregrine announces measures to reduce costs, facilitate profitability and strengthen its operations

Aug 11 2017

BRIEF-Peregrine ‍says "to evaluate strategic options for advancing research and development business​"

* Peregrine Pharmaceuticals Inc - ‍continues to evaluate strategic options for advancing research and development business​

Jul 31 2017

BRIEF-Ronin Trading, SW Investment Management issue letter to Peregrine Pharma employees​

* ‍Ronin Trading and SW Investment Management say issued a letter to Peregrine Pharmaceuticals' employees​

Jul 20 2017

Competitors

Earnings vs. Estimates